OncoZenge: Investor Receives NDRC Approval

OncoZenge AB (publ) ("OncoZenge" or the “Company") has today received confirmation that the NDRC has issued a certificate of approval for the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025.

On January 27th the Company announced the intention to partner with Yangtian Pharma as a new strategic investor in the Company, by entering into an investment agreement that through four tranches of directed share issues to Yangtian Pharma will provide the financing for the phase 3 trial for BupiZenge™ targeting European market approval. The investment is conditional on customary regulatory approvals, through a shareholder resolution in Sweden granted on March 3rd, and the successful completion of the mandatory Overseas Direct Investment (ODI) process in China.

The Company has received notice that the National Development and Reform Commission (NDRC) has completed its review and issued a certificate of approval in support of the investment agreement. 

As announced in the Company's regulatory progress update on April 25th, the mandatory filing with the Ministry of Commerce (MOFCOM) was submitted. The Investor has been informed that a central review is not required, and the file has been transferred for local review.

Upon completion of the review at the Sichuan Provincial Department of Commerce, the Investor will proceed to file with the State Administration of Foreign Exchange (SAFE), as per the ODI process, for administration of the foreign exchange transfers.

Yangtian Pharma and OncoZenge fully expect the process to conclude with a positive outcome, which will release the phase 3 funding in accordance with the investment agreement.



BupiZenge™ – Potential to be the leading treatment for oral pain.